AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2– advanced breast cancer

by Bardia, A., Cartot-Cotton, S., Cohen, P., Cortes, J., Delaloge, S., Hurvitz, S.A, Iwata, H., Kanagavel, D., Liu, Q., O’Shaughnessy, J., Pelekanou, V., Shao, Z.-M
Published 2022

Corrigendum to “Bringing safe and effective therapies to premenopausal women with breast cancer: efforts to broaden eligibility criteria”: [Annals of Oncology 32 (2021) 950-953]...

by Amiri-Kordestani, L., Beaver, J.A, Bhatnagar, V., Bloomquist, E., Booth, B., Cardoso, F., Fashoyin-Aje, L., Gao, J.J, Goetz, M.P, Hodgdon, C., Hurvitz, S.A, Ison, G., Krol, D., Mauro, L., Miller, C.P, Narayan, P., Osgood, C., Pazdur, R., Regan, M.M
Published 2022